A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BLKR201 in Healthy Adult Participants
Latest Information Update: 06 May 2026
At a glance
- Drugs LNK 01006 (Primary)
- Indications Inflammation
- Focus Adverse reactions; Therapeutic Use
- Sponsors Formation Bio
Most Recent Events
- 30 Apr 2026 Status changed from not yet recruiting to recruiting.
- 03 Apr 2026 New trial record